Fig. 3From: Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & IIChange in acute phase reactant (CRP) levels before and after of secretome administration. Mean reduction of CRP in treated group was 77% (P < 0.001)Back to article page